The application of RNAi-based treatments for inflammatory bowel disease

Morten Tobias Jarlstad Olesen; Borja Ballarin Gonzalez; Ken Howard

doi:10.1007/s13346-013-0156-9

The application of RNAi-based treatments for inflammatory bowel disease

Morten Tobias Jarlstad Olesen, Borja Ballarin Gonzalez, Ken Howard

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

12 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) is a chronic, relapsing, idiopathic inflammation of the gastrointestinal tract with no permanent cure. Present immunosuppressive and anti-inflammatory therapies are often ineffective and associated with severe side effects. An RNA interference (RNAi)-based approach in which small interfering RNA (siRNA) mediates specific downregulation of key molecular targets of the IBD inflammatory process may offer a precise, potent and safer alternative to conventional treatments. This review describes the aetiology of Crohn’s disease and ulcerative colitis and the cellular and molecular basis for current treatments to highlight target candidates for an RNAi-based approach. Promising preclinical studies support an RNAi application; however, optimal siRNA designs that maximise potency and development of enabling technologies for site- and cellular-specific delivery are prerequisites for clinical translation.

Original language	English
Journal	Drug Delivery and Translational Research
Volume	4
Issue	1
Pages (from-to)	4-18
ISSN	2190-393X
DOIs	https://doi.org/10.1007/s13346-013-0156-9
Publication status	Published - Feb 2014

Access to Document

10.1007/s13346-013-0156-9

Cite this

@article{15f75cce0e784b58a8518b3c9581d696,

title = "The application of RNAi-based treatments for inflammatory bowel disease",

abstract = "Inflammatory bowel disease (IBD) is a chronic, relapsing, idiopathic inflammation of the gastrointestinal tract with no permanent cure. Present immunosuppressive and anti-inflammatory therapies are often ineffective and associated with severe side effects. An RNA interference (RNAi)-based approach in which small interfering RNA (siRNA) mediates specific downregulation of key molecular targets of the IBD inflammatory process may offer a precise, potent and safer alternative to conventional treatments. This review describes the aetiology of Crohn{\textquoteright}s disease and ulcerative colitis and the cellular and molecular basis for current treatments to highlight target candidates for an RNAi-based approach. Promising preclinical studies support an RNAi application; however, optimal siRNA designs that maximise potency and development of enabling technologies for site- and cellular-specific delivery are prerequisites for clinical translation.",

author = "Olesen, {Morten Tobias Jarlstad} and Gonzalez, {Borja Ballarin} and Ken Howard",

year = "2014",

month = feb,

doi = "10.1007/s13346-013-0156-9",

language = "English",

volume = "4",

pages = "4--18",

journal = "Drug Delivery and Translational Research",

issn = "2190-393X",

publisher = "Springer Publishing Company",

number = "1",

}

The application of RNAi-based treatments for inflammatory bowel disease. / Olesen, Morten Tobias Jarlstad; Gonzalez, Borja Ballarin; Howard, Ken.
In: Drug Delivery and Translational Research, Vol. 4, No. 1, 02.2014, p. 4-18.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - The application of RNAi-based treatments for inflammatory bowel disease

AU - Olesen, Morten Tobias Jarlstad

AU - Gonzalez, Borja Ballarin

AU - Howard, Ken

PY - 2014/2

Y1 - 2014/2

N2 - Inflammatory bowel disease (IBD) is a chronic, relapsing, idiopathic inflammation of the gastrointestinal tract with no permanent cure. Present immunosuppressive and anti-inflammatory therapies are often ineffective and associated with severe side effects. An RNA interference (RNAi)-based approach in which small interfering RNA (siRNA) mediates specific downregulation of key molecular targets of the IBD inflammatory process may offer a precise, potent and safer alternative to conventional treatments. This review describes the aetiology of Crohn’s disease and ulcerative colitis and the cellular and molecular basis for current treatments to highlight target candidates for an RNAi-based approach. Promising preclinical studies support an RNAi application; however, optimal siRNA designs that maximise potency and development of enabling technologies for site- and cellular-specific delivery are prerequisites for clinical translation.

AB - Inflammatory bowel disease (IBD) is a chronic, relapsing, idiopathic inflammation of the gastrointestinal tract with no permanent cure. Present immunosuppressive and anti-inflammatory therapies are often ineffective and associated with severe side effects. An RNA interference (RNAi)-based approach in which small interfering RNA (siRNA) mediates specific downregulation of key molecular targets of the IBD inflammatory process may offer a precise, potent and safer alternative to conventional treatments. This review describes the aetiology of Crohn’s disease and ulcerative colitis and the cellular and molecular basis for current treatments to highlight target candidates for an RNAi-based approach. Promising preclinical studies support an RNAi application; however, optimal siRNA designs that maximise potency and development of enabling technologies for site- and cellular-specific delivery are prerequisites for clinical translation.

U2 - 10.1007/s13346-013-0156-9

DO - 10.1007/s13346-013-0156-9

M3 - Journal article

C2 - 25786614

SN - 2190-393X

VL - 4

SP - 4

EP - 18

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

IS - 1

ER -

The application of RNAi-based treatments for inflammatory bowel disease

Abstract

Access to Document

Fingerprint

Cite this